[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352030-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352030-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","inhibition-of-autophagy-increases-head-and-neck-cancer-sensitivity-to-cetuximab-and-radiation-therapy","Inhibition of autophagy increases head and neck cancer sensitivity to cetuximab and radiation therapy","","Autophagy is a cell survival program that can help head and neck squamous cell carcinoma (HNSCC) withstand treatment stress. Researchers examined whether standard therapy activates autophagy and thereby promotes resistance. Basal autophagy was elevated in cetuximab-resistant cells, and combining cetuximab or radiation with the autophagy inhibitor SAR405 increased growth inhibition in vitro and in vivo. Mechanistic studies showed LAPTM4B/EGFR drive cetuximab-induced autophagy, while PINK1-dependent mitophagy mediates radiation-induced autophagy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/inhibition-of-autophagy-increases-head-and-neck-cancer-sensitivity-to-cetuximab-and-radiation-therapy/352030/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/inhibition-of-autophagy-increases-head-and-neck-cancer-sensitivity-to-cetuximab-and-radiation-therapy/352030.png","ImageObject",300,407,{"name":42,"@type":43},"awa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why was autophagy targeted in head and neck squamous cell carcinoma (HNSCC)?","Question",{"text":63,"@type":64},"Because autophagy supports cell survival under stress and may contribute to resistance to cetuximab and radiation therapy, enabling tumor cells to evade cell death.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What did the study observe in cetuximab-resistant cells?",{"text":68,"@type":64},"Basal autophagy was elevated in cetuximab-resistant cells using an isogenic pair of cetuximab-sensitive and resistant lines.",{"name":70,"@type":61,"acceptedAnswer":71},"How does the autophagy inhibitor SAR405 affect treatment with cetuximab or radiation?",{"text":72,"@type":64},"Combining cetuximab or radiation with SAR405 significantly enhanced growth inhibition in vitro and in vivo compared with either treatment alone.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352030,1790395500,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nInhibition of autophagy increases head and neck cancer sensitivity to cetuximab and radiation therapy  \nYong-Syu Lee1,4, Kwangok P. Nickel1,4, SamanthaT. Bradley1, Justin H. Skiba1,  \nJaimee C. Eckers1, Adam D. Swick1, Rong Hu2,3, Mari Iida1, Zafer Gurel1, Deric L. Wheeler1,3 & Randall J. Kimple1,3􀀍  \nThe five-year survival rate of head and neck squamous cell carcinoma (HNSCC) remains around  \n50% despite advances in treatments over the last 20 years. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), demonstrates limited efficacy both alone and in combination with chemotherapy, with response rates below 20% and 35%, respectively. This underscores the critical need for novel therapeutic strategies and a better understanding of treatment resistance mechanisms in HNSCC. Autophagy, a cell survival process essential to cellular stress for both normal and cancer cells, may contribute to therapeutic resistance in HNSCC. We hypothesized that current treatments might inadvertently activate autophagy, enabling tumor cells to evade  \ncell death. We demonstrated that basal autophagy is elevated in cetuximab-resistant cells using an isogenic pair of cetuximab-sensitive and-resistant cell lines. Furthermore, combining cetuximab or radiation therapy with SAR405, an autophagy inhibitor, significantly enhanced growth inhibition both in vitro and in vivo compared to either treatment alone. Knockdown of LAPTM4B or EGFR significantly reduced cetuximab-induced autophagy. In contrast, radiation-induced autophagy is primarily driven by mitochondrial autophagy (mitophagy). Diminished radiation-induced autophagy was observed by the knockdown of PINK1, a key regulator of mitophagy. These findings highlight that inhibition of autophagy can improve the efficacy of HNSCC treatments and suggest that targeting specific autophagy subtypes may be crucial for developing personalized treatment combinations for HNSCC patients.  \nHead and neck cell carcinoma (HNSCC) is the 6th most common cause of cancer death in the U.S. and is a major health issue worldwide1. Radiation therapy (RT) is a primary treatment option for many HNSCC patients. Cetuximab, monoclonal EGFR antibody, was first approved for treatment of HNSCC in combination with conventional treatments in 20062 and continues to be used this day due to high expression of EGFR in the majority of HNSCC tumors3,4. Despite multimodality care, 5-year survival rates for patients with locally advanced HNSCC remain poor5. There remains significant room for improvements in treatment therapy. Concurrent chemoradiation is commonly recommended to improve both local and distant control6. The addition of cetuximab to standard RT enhances cure rates for newly diagnosed patients with HNSCC by 10%, however it is most often used only for those patients who are unable to tolerate cisplatin-based combinations. Cetuximab is also used in the metastatic setting where approximately 36% of patients respond to cetuximabbased combination therapy, compared to 20% who respond to standard therapy7–12. This indicates that nearly two-thirds of HNSCC patients do not respond to cetuximab-based therapy and highlights the need for a better understanding of therapeutic resistance and the development of novel treatment options for these patients.  \nAutophagy is an evolutionarily conserved cell survival mechanism utilized in response to multiple cellular stresses13. Autophagy begins when the Beclin-1/Vps34 complex generates phosphatidylinositol 3-phosphate (PI3P) pools to nucleate the phagophore. During vesicle elongation, LC3B-I is lipidated to form LC3B-II, which integrates into the autophagosomal membrane to facilitate cargo sequestration. The efficiency of this process is measured as autophagic flux, the rate at which these vesicles fuse with lysosomes for substrate degradation. EGFR signaling has been involved in autophagy. T","cbCairUbfEGHsypu","https://ap.wps.com/l/cbCairUbfEGHsypu","pdf",2439340,14,"English","# Introduction\n## Clinical background of HNSCC and treatment resistance\n## Rationale for targeting autophagy\n# Mechanistic background of autophagy\n## Molecular steps and autophagic flux\n## Links to EGFR signaling and stress responses\n# Experimental findings and therapeutic implications","[{\"question\":\"Why was autophagy targeted in head and neck squamous cell carcinoma (HNSCC)?\",\"answer\":\"Because autophagy supports cell survival under stress and may contribute to resistance to cetuximab and radiation therapy, enabling tumor cells to evade cell death.\"},{\"question\":\"What did the study observe in cetuximab-resistant cells?\",\"answer\":\"Basal autophagy was elevated in cetuximab-resistant cells using an isogenic pair of cetuximab-sensitive and resistant lines.\"},{\"question\":\"How does the autophagy inhibitor SAR405 affect treatment with cetuximab or radiation?\",\"answer\":\"Combining cetuximab or radiation with SAR405 significantly enhanced growth inhibition in vitro and in vivo compared with either treatment alone.\"}]","Inhibition of autophagy increases head and neck cancer sensitivity to cetuximab and radiation therapy | PDF",1790097243,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1354991dc399be1d689896ad6ec4e80d.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/22f7acde5d064a5ec8c1c46e72c5f411.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/978c2429d80257426264e8639a14ae50.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8701f410d66c19f6dfa5cc75a32086e1.webp",980,1287]